Table 2.
Baseline characteristics of the study groups
| Variables | HCs | All TAO | Active TAO | Inactive TAO |
|---|---|---|---|---|
| Number of individuals | 20 | 50 | 39 | 11 |
| Age (years) | 41.60 ± 12.95 | 45.40 ± 12.68 | 46.85 ± 12.76 | 40.27 ± 11.46 |
| Sex (F/M) | 14/6 | 33/17 | 23/16 | 10/1 |
| Smoking, n (%) | - | 38 | 46.2 | 9.1 |
| Disease duration (months) | - | 5.92 ± 5.10 | 6.10 ± 4.55 | 5.27 ± 6.96 |
| CAS | - | 3.36 ± 1.14 | 3.79 ± 0.86 | 1.82 ± 0.41 |
| FT3 (pmol/L) | - | 6.16 ± 3.82 | 6.47 ± 4.25 | 5.07 ± 1.11 |
| FT4 (pmol/L) | - | 18.32 ± 9.78 | 18.86 ± 10.95 | 16.41 ± 2.72 |
| TSH (mIU/L) | - | 1.87 ± 2.49 | 1.88 ± 2.60 | 1.81 ± 2.14 |
| TRAb (IU/L) | - | 8.99 ± 11.34 | 9.37 ± 11.21 | 7.63 ± 12.24 |
The numeric data are reported as the mean ± standard deviation
TAO thyroid-associated ophthalmopathy, F female, M male, CAS clinical activity score, FT4 free thyroxine, FT3 free triiodothyronine, TSH thyroid-stimulating hormone, TRAb thyroid-stimulating hormone receptor antibody